Daiichi Sankyo Q1 FY26 operating profit falls 12% to JPY 85.1 billion; revenue rises 21.1% to JPY 574.7 billionPUBT·9 hours agoDSNKY-11.90%4568
Daiichi Sankyo, AstraZeneca Datroway wins EU approval for first-line metastatic TNBC in non-immunotherapy patientsPUBT·11 hours agoAZN-0.71%DSNKY-11.90%
Daiichi Sankyo Company: Oncology-driven revenue growth and FX gains lifted results, but profit fell on higher costsQuartr·13 hours agoDSNKY-11.90%4568
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy | AZN Stock NewsStockTitan·19 hours agoAZN-0.71%DSNKY-11.90%
Toyota Stock, SoftBank And Daiichi Sankyo Offer Reliable Japan Dividend IncomeSimplywall·Jul 27 at 10:13 AMTM-1.15%DSNKY-11.90%
Daiichi Sankyo Co., Ltd. - Sponsored ADR (OTCMKTS:DSNKY) Short Interest Up 1,183.6% in JulyMarket Beat·Jul 24 at 06:00 PMDSNKY-11.90%4568
Daiichi Sankyo’s Enhertu plus pertuzumab wins EU CHMP backing for first-line HER2+ metastatic breast cancerPUBT·Jul 24 at 06:01 AMDSNKY-11.90%4568
Canon Stock And 2 Japanese Dividend Stocks Offering Steady IncomeSimplywall·Jul 18 at 12:02 AM4568SFTBY+2.46%
Key facts: Wainua fails CV trial; Enhertu nears UK price dealTradingView·Jul 9 at 02:14 AMAZNAZN-0.71%
AstraZeneca Nears Enhertu Deal After 300 Million UK InvestmentGuruFocus·Jul 8 at 01:46 PMAZN-0.71%AZN
AstraZeneca Advances Rare Bone Disease Pipeline While Enhertu Expands In Europebenzinga_article·Jun 29 at 11:59 AMAZNAZN-0.71%
Enhertu® Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and Antibody Drug Conjugate for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors | AZN Stock NewsStockTitan·Jun 28 at 05:30 PMAZNDSNKY-11.90%
